原发性血小板减少性紫癜(ITP)是1种自身免疫性疾病,激素、切脾、免疫抑制剂是基本疗法。1983年Salama等报告用抗Rh(D)抗体治疗。本文作者应用该药治疗1例ITP。患者35岁,女性,因紫斑、月经过多(血小板6×10~9/L),骨髓巨核细胞增多、血清抗血小板抗体阳性而诊断ITP。先后经输血小板、激素及免疫球蛋白大剂量静注(400mg/kg,5天)、脾切除等治疗,血小板升至20×10~9/L。切脾1个月后,抗Rh(D)250μg肌注(此时强的松已减至25mg/d),肌注后血小板成倍增加,2个月后升至100×10~9/L(此间激素逐渐减量)。现认为多数成人慢性型ITP患者很难自发缓解。ITP患者静注抗Rh(D)增加血小板数,其作用机理也 Primary thrombocytopenic purpura (ITP) is an autoimmune disease, hormone, spleen, immunosuppressive agents are the basic therapy. In 1983, Salama et al reported treatment with anti-Rh (D) antibodies. The author of the drug treatment of 1 case of ITP. The patient, age 35, was diagnosed with ITP because of purpura, menorrhagia (platelets 6 × 10 ~ 9 / L), increased bone marrow megakaryocytes, and serum anti-platelet antibodies. Has been transfused platelets, hormones and immunoglobulin high-dose intravenous injection (400mg / kg, 5 days), splenectomy and other treatment, platelets rose to 20 × 10 ~ 9 / L. One month after splenectomy, anti-Rh (D) 250μg intramuscular injection (at this time prednisone has been reduced to 25mg / d), intramuscular injection of platelets multiplied, 2 months later increased to 100 × 10 ~ 9 / L (Here gradually tapering hormone). Now that most adults with chronic ITP patients is difficult to spontaneous remission. ITP patients intravenously anti-Rh (D) increase in platelet count, its mechanism of action also